Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 5,000 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Edwards Lifesciences Stock Up 1.1 %

EW traded up $0.71 during midday trading on Wednesday, reaching $66.52. The company’s stock had a trading volume of 3,495,653 shares, compared to its average volume of 4,633,185. The stock’s 50-day moving average is $67.47 and its 200-day moving average is $76.51. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $39.23 billion, a price-to-earnings ratio of 9.56, a PEG ratio of 3.70 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.59 earnings per share. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Crewe Advisors LLC acquired a new stake in Edwards Lifesciences during the 1st quarter valued at approximately $28,000. First Community Trust NA purchased a new stake in shares of Edwards Lifesciences during the second quarter worth $29,000. Webster Bank N. A. purchased a new stake in shares of Edwards Lifesciences during the second quarter worth $39,000. Versant Capital Management Inc grew its holdings in shares of Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 326 shares during the period. Finally, Prospera Private Wealth LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at about $32,000. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Stifel Nicolaus reduced their price target on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a report on Thursday, July 25th. Bank of America cut Edwards Lifesciences from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $105.00 to $75.00 in a research note on Thursday, July 25th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Wells Fargo & Company dropped their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a report on Friday, October 11th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.